Medical Marketing & Media: Biologic/Biosimilar & Lupus Markets

Back Bay provided expertise for two articles in Medical Marketing & Media (MM&M)

• In “MedImmune goes after challenging lupus market,” (MM&M, April 26, 2017) Dr. Gauldie noted: “The heterogeneous patient population makes lupus difficult from a trial point of view . . . developers must target patient subsets.”He added that many failures “have boiled down to choosing the right patient population and identifying the correct endpoint for study.” The full article is available at this link.

• In “Drugmakers battle for slice of Humira’s billions,” (MM&M April 26, 2016), MM&M explores the fast-growing biologics segment, “biologics can only hold back biosimilars for so long.”MM&M notes that “the U.S. biosimilar market could take a few cues from abroad. In Norway, for instance, the government-funded an interchangeability study for a Remicade biosimilar. Proving interchangeability had a profound effect on its healthcare system. Major health insurers ponying up as study sponsors would prove a viable parallel.”

  “The negotiating power that payers have may be the difference in setting affordable prices for biosimilars,” explained Dr. Gauldie.

  The full article is available at this link.